Li Peizhi, An Guohua
Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA, USA.
J Clin Pharmacol. 2025 May;65(5):535-549. doi: 10.1002/jcph.6181. Epub 2025 Jan 20.
Recreational cannabis use has increased notably in the United States in the past decade, with a recent surge in oral consumption. This trend has raised concerns about driving under the influence. Current cannabis-impaired driving laws lack standardization, with some states implementing blood Δ9-tetrahydrocannabinol (THC) per se limits (1, 2, and 5 ng/mL). However, these limits have been criticized for their inaccuracy and unreliability, highlighting the need for legal refinement. Addressing this issue requires understanding the complex pharmacokinetics (PK) and pharmacodynamics (PD) of THC, cannabis's primary psychoactive component, which can be characterized using a population PK model. However, existing PK models mainly focus on inhalation data and do not account for the growing number of oral cannabis users. To bridge this gap, a semi-mechanistic population PK model was developed using data from 10 published studies following intravenous or oral administration of cannabis to characterize THC and its metabolites in oral users. Simulated THC plasma concentrations for doses from 2.5 mg to 100 mg in frequent and occasional users were used to evaluate the effectiveness of existing per se limits. Results showed that the 1 ng/mL limit was least effective due to a high risk of false positives, while the 2 and 5 ng/mL limits remain inconclusive due to limited PD data linking blood THC levels to impairment. These findings suggest that the existing per se laws may not fully address the complexity of cannabis impairment, underscoring the need for further research and refinement of cannabis-impaired driving laws.
在过去十年中,美国娱乐性大麻的使用显著增加,近期口服消费呈激增态势。这一趋势引发了对大麻影响下驾驶的担忧。当前关于大麻影响下驾驶的法律缺乏标准化,一些州实施了血液中Δ9-四氢大麻酚(THC)本身的限量规定(1纳克/毫升、2纳克/毫升和5纳克/毫升)。然而,这些限量规定因其不准确和不可靠而受到批评,凸显了法律完善的必要性。解决这一问题需要了解THC(大麻的主要精神活性成分)复杂的药代动力学(PK)和药效学(PD),这可以通过群体PK模型来表征。然而,现有的PK模型主要关注吸入数据,并未考虑到口服大麻使用者数量的不断增加。为了填补这一空白,利用10项已发表研究的数据开发了一个半机制群体PK模型,这些研究涉及静脉注射或口服大麻后THC及其代谢物在口服使用者中的情况。通过模拟频繁使用者和偶尔使用者服用2.5毫克至100毫克剂量后的THC血浆浓度,来评估现有本身限量规定的有效性。结果表明,1纳克/毫升的限量规定因假阳性风险高而效果最差,而2纳克/毫升和5纳克/毫升的限量规定由于将血液THC水平与损害联系起来的PD数据有限,结果仍不明确。这些发现表明,现有的本身法律可能无法充分应对大麻损害的复杂性,强调了进一步研究和完善大麻影响下驾驶法律的必要性。